<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741271</url>
  </required_header>
  <id_info>
    <org_study_id>0887A-087</org_study_id>
    <secondary_id>MK-0887A-087</secondary_id>
    <secondary_id>2009-010110-30</secondary_id>
    <nct_id>NCT02741271</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)</brief_title>
  <official_title>A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared With Mometasone Furoate (MF, MK-0887 [SCH032088]), in Children With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the 12-week efficacy and 24-week safety of mometasone furoate/formoterol
      fumarate (MF/F) 100/10 mcg and mometasone furate (MF) 100 mcg, both administered twice daily
      (BID) via metered-dose inhaler (MDI) in children aged 5 to 11 years with persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2016</start_date>
  <completion_date type="Actual">December 4, 2017</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>1:1 randomization to double-blinded MF/F MDI 100/10 mcg BID and MF MDI 100 mcg BID</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning (AM) Post-Dose % Predicted Forced Expiratory Volume in One Second (FEV1) in the Area Under the Curve (AUC)0-60</measure>
    <time_frame>Baseline, and average of Day 1, Weeks 1, 4, 8, and 12</time_frame>
    <description>This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 60 minutes post-dose (at 0, 5, 15, 30 and 60 minutes) and averaged across study visits in the Treatment Period (Day 1, Week 1, Week 4, Week 8 and Week 12) compared to Baseline. Baseline was the average of % predicted FEV1 values at 30 min and 0 min pre-dose. At each visit, the area under the curve is calculated over the post-dose timepoints. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count (Percentage) of Participants Experiencing At Least One Adverse Event (AE)</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count (Percentage) of Participants Discontinuing From Study Medication Due to An AE</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline AM Post-Dose Percent Predicted FEV1 on Day 1 of Treatment</measure>
    <time_frame>Baseline and Day 1, measured at 4 hr, 2 hr and 60, 30, 15, and 5 min, post-dose time points</time_frame>
    <description>The key secondary objective was to determine the onset of action for the efficacy of MF/F MDI 100/10 mcg BID, compared with MF MDI 100 mcg BID. The post-dose AM % predicted FEV1 was averaged sequentially, and the change from baseline on Day 1 was assessed. This key secondary endpoint was controlled for multiplicity in a step-down fashion, based on trial success defined as a statistically significant improvement in the primary endpoint for MF/F vs MF. Missing data were imputed using control-based multiple imputations with the cLDA model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline AM Post-Dose % Predicted FEV1 AUC 0-4 Hours on Day 1 and Week 12 of Treatment</measure>
    <time_frame>Baseline, Day 1 and Week 12</time_frame>
    <description>This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 4 hours post-dose on Day 1 and Week 12 compared to Baseline. Baseline was the average of 30 and 0 minutes pre-dose % predicted FEV1 values. The AUC was calculated over the scheduled timepoints of 0 min, 5 min, 15 min, 30 min, 60 min, 2 hr and 4 hr post-dose. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AM Pre-Dose % Predicted FEV1 With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment</measure>
    <time_frame>Baseline and Weeks 4, 8, and 12 (Averaged)</time_frame>
    <description>The change from baseline in AM pre-dose % predicted FEV1 with MF/F MDI 100/10 mcg BID vs MF MDI 100 mcg BID averaged over 12 weeks treatment was assessed. This secondary analysis of the change from baseline used the cLDA method without multiple imputation. A model-based MAR approach was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Daily Use of Short-Acting Beta-Agonist (SABA) Rescue Medication With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment</measure>
    <time_frame>Baseline and Weeks 1-12 (Averaged)</time_frame>
    <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the change from baseline in total daily short-acting beta-agonist (SABA) use (puffs per day) was averaged and assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for as-needed relief of asthma symptoms. This secondary analysis of the change from baseline used the cLDA method without multiple imputation.A model-based MAR approach was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Using SABA Rescue Medication Across Weeks 1-12 of the Treatment Period</measure>
    <time_frame>Baseline and Weeks 1-12 (Averaged)</time_frame>
    <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the number of participants using SABA rescue medication in Weeks 1-12 (individually) of the double-blind treatment period was assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for as-needed relief of asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Whose SABA Rescue Medication Use Increased Across Weeks 1-12 of the Treatment Period</measure>
    <time_frame>Weeks 1-12 (Averaged)</time_frame>
    <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the number of participants whose use of SABA rescue medication increased in Weeks 1-12 (individually) of the double-blind treatment period was assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for relief of asthma symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to 12 Hours (AUC0-12)</measure>
    <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
    <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to Time of Last Measurable Concentration (AUC0-last)</measure>
    <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
    <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Mometsone Furoate</measure>
    <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
    <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Mometsone Furoate</measure>
    <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
    <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF MDI 100 mcg BID (Open Label)</intervention_name>
    <description>Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.</description>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <other_name>ASMANEX HFA®</other_name>
    <other_name>SCH 032088 (MK-0887)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF/F MDI 100/10 mcg BID</intervention_name>
    <description>After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.</description>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
    <other_name>DULERA®/ZENHALE®</other_name>
    <other_name>SCH 418131 (MK-0887A)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF MDI 100 mcg BID</intervention_name>
    <description>After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.</description>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <other_name>ASMANEX HFA®</other_name>
    <other_name>SCH 032088 (MK-0887)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol/Salbutamol PRN</intervention_name>
    <description>Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.</description>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone/Prednisolone</intervention_name>
    <description>Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.</description>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_label>MF/F MDI 100/10 mcg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of asthma of ≥ 6-months duration according to the Global Initiative
             for Asthma (GINA) guidelines

          -  Has asthma that is adequately controlled on a stable dose of inhaled corticosteroid
             (ICS) combined with long-acting beta-agonist (LABA) ≥ 4 weeks

          -  Is able to demonstrate an FEV1 &gt;60% and ≤90% predicted

          -  Is able to demonstrate an increase in absolute FEV1 of at least 12% within 30 minutes
             after administration of albuterol/salbutamol.

          -  Is able to use an MDI (without spacer), use a peak flow meter, and perform spirometry
             correctly.

          -  Is willing (with consent of their parent(s)/guardian) to discontinue previously
             prescribed asthma medication, if there is no inherent harm in changing the
             participant's current asthma therapy.

          -  Has laboratory tests that are clinically acceptable to the investigator.

        Exclusion Criteria:

          -  Requires &gt;8 inhalations per day of albuterol (100 mcg per actuation), and/or &gt;2
             nebulized treatments per day of 2.5 mg albuterol on any 2 consecutive days

          -  Has a clinical worsening of asthma that results in emergency room visit (for an asthma
             exacerbation), hospitalization due to asthma, or treatment with additional, excluded
             asthma medication (other than SABA) between the Screening and Baseline visits.

          -  Is considered by the investigator to have unstable asthma at the end of the run-in
             period

          -  Has had &gt; 4 asthma exacerbations (defined as a worsening of asthma requiring systemic
             corticosteroid use and/or ≥ 24-hour stay in an emergency department, urgent care
             center, or hospital) within 1 year prior to visit 1

          -  Has had a history of life-threatening asthma

          -  Has a clinically significant condition or situation, other than the condition being
             studied which may interfere with trial evaluations, participant safety, or optimal
             participation in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Weinstein CLJ, Gates D, Zhang X, Varnell T, Mok W, Vermeulen JH, Amar NJ, Jain N. A phase 3 study evaluating the safety and efficacy of a pediatric dose of mometasone furoate with and without formoterol for persistent asthma. Pediatr Pulmonol. 2020 Apr;55(4):882-889. doi: 10.1002/ppul.24667. Epub 2020 Feb 5.</citation>
    <PMID>32022483</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <results_first_submitted>March 25, 2019</results_first_submitted>
  <results_first_submitted_qc>May 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2019</results_first_posted>
  <disposition_first_submitted>February 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 28, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 6, 2018</disposition_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02741271/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MF/F MDI 100/10 mcg BID</title>
          <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
        </group>
        <group group_id="P2">
          <title>MF MDI 100 mcg BID</title>
          <description>MF administered by MDI, given as 100 mcg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF/F MDI 100/10 mcg BID</title>
          <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
        </group>
        <group group_id="B2">
          <title>MF MDI 100 mcg BID</title>
          <description>MF administered by MDI, given as 100 mcg BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" spread="1.7"/>
                    <measurement group_id="B2" value="9.1" spread="1.7"/>
                    <measurement group_id="B3" value="9.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning (AM) Post-Dose % Predicted Forced Expiratory Volume in One Second (FEV1) in the Area Under the Curve (AUC)0-60</title>
        <description>This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 60 minutes post-dose (at 0, 5, 15, 30 and 60 minutes) and averaged across study visits in the Treatment Period (Day 1, Week 1, Week 4, Week 8 and Week 12) compared to Baseline. Baseline was the average of % predicted FEV1 values at 30 min and 0 min pre-dose. At each visit, the area under the curve is calculated over the post-dose timepoints. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.</description>
        <time_frame>Baseline, and average of Day 1, Weeks 1, 4, 8, and 12</time_frame>
        <population>All participants who received at least one dose of randomized trial medication with at least one primary efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning (AM) Post-Dose % Predicted Forced Expiratory Volume in One Second (FEV1) in the Area Under the Curve (AUC)0-60</title>
          <description>This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 60 minutes post-dose (at 0, 5, 15, 30 and 60 minutes) and averaged across study visits in the Treatment Period (Day 1, Week 1, Week 4, Week 8 and Week 12) compared to Baseline. Baseline was the average of % predicted FEV1 values at 30 min and 0 min pre-dose. At each visit, the area under the curve is calculated over the post-dose timepoints. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.</description>
          <population>All participants who received at least one dose of randomized trial medication with at least one primary efficacy evaluation.</population>
          <units>Percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.21" spread="11.44"/>
                    <measurement group_id="O2" value="78.48" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" spread="8.29"/>
                    <measurement group_id="O2" value="3.96" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method, using the constrained Longitudinal Data Analysis (cLDA) model for missing data</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>5.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.21</ci_lower_limit>
            <ci_upper_limit>7.20</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count (Percentage) of Participants Experiencing At Least One Adverse Event (AE)</title>
        <description>An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Up to 26 weeks</time_frame>
        <population>All randomized participants who received at least one dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All treated participants</description>
          </group>
        </group_list>
        <measure>
          <title>Count (Percentage) of Participants Experiencing At Least One Adverse Event (AE)</title>
          <description>An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All randomized participants who received at least one dose of trial medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Count (Percentage) of Participants Discontinuing From Study Medication Due to An AE</title>
        <description>An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants who received at least one dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All treated participants</description>
          </group>
        </group_list>
        <measure>
          <title>Count (Percentage) of Participants Discontinuing From Study Medication Due to An AE</title>
          <description>An Adverse Event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All randomized participants who received at least one dose of trial medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline AM Post-Dose Percent Predicted FEV1 on Day 1 of Treatment</title>
        <description>The key secondary objective was to determine the onset of action for the efficacy of MF/F MDI 100/10 mcg BID, compared with MF MDI 100 mcg BID. The post-dose AM % predicted FEV1 was averaged sequentially, and the change from baseline on Day 1 was assessed. This key secondary endpoint was controlled for multiplicity in a step-down fashion, based on trial success defined as a statistically significant improvement in the primary endpoint for MF/F vs MF. Missing data were imputed using control-based multiple imputations with the cLDA model.</description>
        <time_frame>Baseline and Day 1, measured at 4 hr, 2 hr and 60, 30, 15, and 5 min, post-dose time points</time_frame>
        <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline AM Post-Dose Percent Predicted FEV1 on Day 1 of Treatment</title>
          <description>The key secondary objective was to determine the onset of action for the efficacy of MF/F MDI 100/10 mcg BID, compared with MF MDI 100 mcg BID. The post-dose AM % predicted FEV1 was averaged sequentially, and the change from baseline on Day 1 was assessed. This key secondary endpoint was controlled for multiplicity in a step-down fashion, based on trial success defined as a statistically significant improvement in the primary endpoint for MF/F vs MF. Missing data were imputed using control-based multiple imputations with the cLDA model.</description>
          <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation</population>
          <units>Percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.21" spread="11.44"/>
                    <measurement group_id="O2" value="78.48" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (4 hr post-dose on Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.61" spread="10.31"/>
                    <measurement group_id="O2" value="5.68" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (2 hr post-dose on Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.71" spread="9.53"/>
                    <measurement group_id="O2" value="5.87" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (60 min post-dose on Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.05" spread="8.51"/>
                    <measurement group_id="O2" value="4.92" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (30 min post-dose on Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="7.02"/>
                    <measurement group_id="O2" value="3.05" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (15 min post-dose on Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="7.12"/>
                    <measurement group_id="O2" value="1.38" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (5 min post-dose on Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="6.93"/>
                    <measurement group_id="O2" value="0.95" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>6.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.53</ci_lower_limit>
            <ci_upper_limit>8.56</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 4 hr Post-Dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>7.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.74</ci_lower_limit>
            <ci_upper_limit>9.35</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 2 hr Post-Dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>6.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.09</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 60 min Post-Dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>6.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.10</ci_lower_limit>
            <ci_upper_limit>8.67</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 30 min Post-Dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>6.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.89</ci_lower_limit>
            <ci_upper_limit>8.39</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 15 min Post-Dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA with multiple imputation</method>
            <method_desc>Primary Analysis Method</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>4.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.50</ci_lower_limit>
            <ci_upper_limit>5.91</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 5 min Post-Dose</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline AM Post-Dose % Predicted FEV1 AUC 0-4 Hours on Day 1 and Week 12 of Treatment</title>
        <description>This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 4 hours post-dose on Day 1 and Week 12 compared to Baseline. Baseline was the average of 30 and 0 minutes pre-dose % predicted FEV1 values. The AUC was calculated over the scheduled timepoints of 0 min, 5 min, 15 min, 30 min, 60 min, 2 hr and 4 hr post-dose. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.</description>
        <time_frame>Baseline, Day 1 and Week 12</time_frame>
        <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline AM Post-Dose % Predicted FEV1 AUC 0-4 Hours on Day 1 and Week 12 of Treatment</title>
          <description>This endpoint reflects changes in lung function data (forced expiratory volume in 1 second) measured across 0 to 4 hours post-dose on Day 1 and Week 12 compared to Baseline. Baseline was the average of 30 and 0 minutes pre-dose % predicted FEV1 values. The AUC was calculated over the scheduled timepoints of 0 min, 5 min, 15 min, 30 min, 60 min, 2 hr and 4 hr post-dose. Units are standardized to percent predicted FEV1 by dividing the AUC calculation by the duration of the observed AUC.</description>
          <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation.</population>
          <units>Percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.21" spread="11.44"/>
                    <measurement group_id="O2" value="78.48" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="5.35"/>
                    <measurement group_id="O2" value="2.70" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.56" spread="11.20"/>
                    <measurement group_id="O2" value="4.87" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>Secondary Outcome Measure on Day 1</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>6.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.36</ci_lower_limit>
            <ci_upper_limit>8.27</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 4 hr Post-Dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>cLDA</method>
            <method_desc>Secondary Outcome Measure at Week 12</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>3.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>6.26</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference at 4 hr Post-Dose</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AM Pre-Dose % Predicted FEV1 With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment</title>
        <description>The change from baseline in AM pre-dose % predicted FEV1 with MF/F MDI 100/10 mcg BID vs MF MDI 100 mcg BID averaged over 12 weeks treatment was assessed. This secondary analysis of the change from baseline used the cLDA method without multiple imputation. A model-based MAR approach was used for missing data.</description>
        <time_frame>Baseline and Weeks 4, 8, and 12 (Averaged)</time_frame>
        <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation across the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AM Pre-Dose % Predicted FEV1 With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment</title>
          <description>The change from baseline in AM pre-dose % predicted FEV1 with MF/F MDI 100/10 mcg BID vs MF MDI 100 mcg BID averaged over 12 weeks treatment was assessed. This secondary analysis of the change from baseline used the cLDA method without multiple imputation. A model-based MAR approach was used for missing data.</description>
          <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation across the treatment period.</population>
          <units>Percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.21" spread="11.44"/>
                    <measurement group_id="O2" value="78.22" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Weeks 4, 8, and 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="7.15"/>
                    <measurement group_id="O2" value="0.44" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.197</p_value>
            <method>cLDA</method>
            <method_desc>Secondary Outcome Measure</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
            <estimate_desc>Between-Treatment Difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Daily Use of Short-Acting Beta-Agonist (SABA) Rescue Medication With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment</title>
        <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the change from baseline in total daily short-acting beta-agonist (SABA) use (puffs per day) was averaged and assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for as-needed relief of asthma symptoms. This secondary analysis of the change from baseline used the cLDA method without multiple imputation.A model-based MAR approach was used for missing data.</description>
        <time_frame>Baseline and Weeks 1-12 (Averaged)</time_frame>
        <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Daily Use of Short-Acting Beta-Agonist (SABA) Rescue Medication With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment</title>
          <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the change from baseline in total daily short-acting beta-agonist (SABA) use (puffs per day) was averaged and assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for as-needed relief of asthma symptoms. This secondary analysis of the change from baseline used the cLDA method without multiple imputation.A model-based MAR approach was used for missing data.</description>
          <population>All participants who received at least one dose of randomized trial medication with at least one efficacy evaluation</population>
          <units>Puffs per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.66"/>
                    <measurement group_id="O2" value="0.13" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Over Weeks 1-12 (Average)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.58"/>
                    <measurement group_id="O2" value="-0.02" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Using SABA Rescue Medication Across Weeks 1-12 of the Treatment Period</title>
        <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the number of participants using SABA rescue medication in Weeks 1-12 (individually) of the double-blind treatment period was assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for as-needed relief of asthma symptoms.</description>
        <time_frame>Baseline and Weeks 1-12 (Averaged)</time_frame>
        <population>Data were provided for all participants who received at least one dose of randomized trial medication and had at least one efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Using SABA Rescue Medication Across Weeks 1-12 of the Treatment Period</title>
          <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the number of participants using SABA rescue medication in Weeks 1-12 (individually) of the double-blind treatment period was assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for as-needed relief of asthma symptoms.</description>
          <population>Data were provided for all participants who received at least one dose of randomized trial medication and had at least one efficacy evaluation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Whose SABA Rescue Medication Use Increased Across Weeks 1-12 of the Treatment Period</title>
        <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the number of participants whose use of SABA rescue medication increased in Weeks 1-12 (individually) of the double-blind treatment period was assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for relief of asthma symptoms.</description>
        <time_frame>Weeks 1-12 (Averaged)</time_frame>
        <population>Data were provided for all participants who received at least one dose of randomized trial medication and had at least one efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 100/10 mcg BID</title>
            <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>MF administered by MDI, given as 100 mcg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Whose SABA Rescue Medication Use Increased Across Weeks 1-12 of the Treatment Period</title>
          <description>To evaluate the efficacy of MF/F MDI 100/10 mcg BID compared with MF MDI 100 mcg BID, the number of participants whose use of SABA rescue medication increased in Weeks 1-12 (individually) of the double-blind treatment period was assessed. All participants received SABA MDIs (albuterol 90 mcg or salbutamol 100 mcg) for relief of asthma symptoms.</description>
          <population>Data were provided for all participants who received at least one dose of randomized trial medication and had at least one efficacy evaluation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to 12 Hours (AUC0-12)</title>
        <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
        <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
        <population>Participants who consented to take part in the PK sub-trial and had evaluable data for AUC(0-12).</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MF/F 100/10 mcg and MF 100 mcg</title>
            <description>MF/F 100/10 mcg BID or MF 100 mcg BID, administered by MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to 12 Hours (AUC0-12)</title>
          <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
          <population>Participants who consented to take part in the PK sub-trial and had evaluable data for AUC(0-12).</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to Time of Last Measurable Concentration (AUC0-last)</title>
        <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
        <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
        <population>Participants who consented to take part in the PK sub-trial and had evaluable data for AUC(0-last).</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MF/F 100/10 mcg and MF 100 mcg</title>
            <description>MF/F 100/10 mcg BID or MF 100 mcg BID, administered by MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to Time of Last Measurable Concentration (AUC0-last)</title>
          <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
          <population>Participants who consented to take part in the PK sub-trial and had evaluable data for AUC(0-last).</population>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Mometsone Furoate</title>
        <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
        <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
        <population>Participants who consented to take part in the PK sub-trial and had evaluable data for Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MF/F 100/10 mcg and MF 100 mcg</title>
            <description>MF/F 100/10 mcg BID or MF 100 mcg BID, administered by MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Mometsone Furoate</title>
          <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
          <population>Participants who consented to take part in the PK sub-trial and had evaluable data for Cmax.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Mometsone Furoate</title>
        <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
        <time_frame>Predose, 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12</time_frame>
        <population>Participants who consented to take part in the PK sub-trial and had evaluable data for Tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MF/F 100/10 mcg and MF 100 mcg</title>
            <description>MF/F 100/10 mcg BID or MF 100 mcg BID, administered by MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Mometsone Furoate</title>
          <description>Blood samples were collected predose, and 0.75, 1.5, 3, 8, and 12 hours postdose at Week 12 in a subset of participants who consented to take part in a PK sub-trial. Per protocol, descriptive MF pharmacokinetics were summarized without regard to treatment assignment.</description>
          <population>Participants who consented to take part in the PK sub-trial and had evaluable data for Tmax.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="0.50" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 26 weeks</time_frame>
      <desc>All participants who received double-blind treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>MF/F MDI 100/10 mcg BID</title>
          <description>MF/F administered by MDI, given as 100/10 mcg BID</description>
        </group>
        <group group_id="E2">
          <title>MF MDI 100 mcg BID</title>
          <description>MF administered by MDI, given as 100 mcg BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

